Multiplexed on-yeast serological assay for immune escape screening of SARS-CoV-2 variants
Summary: The emergence of the SARS-CoV-2 Omicron variant altered patient risk profiles and shifted the trajectory of the COVID-19 pandemic. Therefore, sensitive serological tests capable of analyzing patient IgG responses to multiple variants in parallel are highly desirable. Here, we present an ada...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004223007253 |
| _version_ | 1797835698265391104 |
|---|---|
| author | Joanan Lopez-Morales Rosario Vanella Tamara Utzinger Valentin Schittny Julia Hirsiger Michael Osthoff Christoph T. Berger Yakir Guri Michael A. Nash |
| author_facet | Joanan Lopez-Morales Rosario Vanella Tamara Utzinger Valentin Schittny Julia Hirsiger Michael Osthoff Christoph T. Berger Yakir Guri Michael A. Nash |
| author_sort | Joanan Lopez-Morales |
| collection | DOAJ |
| description | Summary: The emergence of the SARS-CoV-2 Omicron variant altered patient risk profiles and shifted the trajectory of the COVID-19 pandemic. Therefore, sensitive serological tests capable of analyzing patient IgG responses to multiple variants in parallel are highly desirable. Here, we present an adaptable serological test based on yeast surface display and serum biopanning that characterizes immune profiles against SARS-CoV-2 Wuhan (B lineage), Delta (B.1.617.2 lineage), and Omicron (B.1.1.529 lineage) receptor-binding domain (RBD) variants. We examined IgG titers from 30 serum samples from COVID-19-convalescent and vaccinated cohorts in Switzerland, and assessed the relative affinity of polyclonal serum IgG for RBD domains. We demonstrate that serum IgGs from patients recovered from severe COVID-19 between March-June 2021 bound tightly to both original Wuhan and Delta RBD variants, but failed to recognize Omicron RBDs, representing an affinity loss of >10– to 20-fold. Our yeast immunoassay is easily tailored, expandable and parallelized with newly emerging RBD variants. |
| first_indexed | 2024-04-09T14:57:47Z |
| format | Article |
| id | doaj.art-acba1905787e4d8683cc950f4cf31e66 |
| institution | Directory Open Access Journal |
| issn | 2589-0042 |
| language | English |
| last_indexed | 2024-04-09T14:57:47Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj.art-acba1905787e4d8683cc950f4cf31e662023-05-02T04:05:13ZengElsevieriScience2589-00422023-05-01265106648Multiplexed on-yeast serological assay for immune escape screening of SARS-CoV-2 variantsJoanan Lopez-Morales0Rosario Vanella1Tamara Utzinger2Valentin Schittny3Julia Hirsiger4Michael Osthoff5Christoph T. Berger6Yakir Guri7Michael A. Nash8Institute of Physical Chemistry, Department of Chemistry, University of Basel, Basel 4058, Switzerland; Swiss Nanoscience Institute, University of Basel, 4056 Basel, Switzerland; Department of Biosystems Science and Engineering, ETH Zurich, 4058 Basel, Switzerland; Botnar Research Centre for Child Health (BRCCH), 4051 Basel, SwitzerlandInstitute of Physical Chemistry, Department of Chemistry, University of Basel, Basel 4058, Switzerland; Department of Biosystems Science and Engineering, ETH Zurich, 4058 Basel, Switzerland; Botnar Research Centre for Child Health (BRCCH), 4051 Basel, Switzerland; National Center for Research Competence (NCCR) Molecular Systems Engineering, 4058 Basel, SwitzerlandInstitute of Physical Chemistry, Department of Chemistry, University of Basel, Basel 4058, Switzerland; Swiss Nanoscience Institute, University of Basel, 4056 Basel, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zurich, 4058 Basel, SwitzerlandDepartment of Biomedicine, University of Basel, 4056 Basel, SwitzerlandBotnar Research Centre for Child Health (BRCCH), 4051 Basel, Switzerland; Department of Internal Medicine, University Hospital Basel, 4056 Basel, SwitzerlandBotnar Research Centre for Child Health (BRCCH), 4051 Basel, Switzerland; Department of Biomedicine, University of Basel, 4056 Basel, Switzerland; University Center for Immunology, University Hospital Basel, Basel 4056, SwitzerlandBotnar Research Centre for Child Health (BRCCH), 4051 Basel, Switzerland; Department of Internal Medicine, University Hospital Basel, 4056 Basel, SwitzerlandInstitute of Physical Chemistry, Department of Chemistry, University of Basel, Basel 4058, Switzerland; Swiss Nanoscience Institute, University of Basel, 4056 Basel, Switzerland; Department of Biosystems Science and Engineering, ETH Zurich, 4058 Basel, Switzerland; Botnar Research Centre for Child Health (BRCCH), 4051 Basel, Switzerland; National Center for Research Competence (NCCR) Molecular Systems Engineering, 4058 Basel, Switzerland; Corresponding authorSummary: The emergence of the SARS-CoV-2 Omicron variant altered patient risk profiles and shifted the trajectory of the COVID-19 pandemic. Therefore, sensitive serological tests capable of analyzing patient IgG responses to multiple variants in parallel are highly desirable. Here, we present an adaptable serological test based on yeast surface display and serum biopanning that characterizes immune profiles against SARS-CoV-2 Wuhan (B lineage), Delta (B.1.617.2 lineage), and Omicron (B.1.1.529 lineage) receptor-binding domain (RBD) variants. We examined IgG titers from 30 serum samples from COVID-19-convalescent and vaccinated cohorts in Switzerland, and assessed the relative affinity of polyclonal serum IgG for RBD domains. We demonstrate that serum IgGs from patients recovered from severe COVID-19 between March-June 2021 bound tightly to both original Wuhan and Delta RBD variants, but failed to recognize Omicron RBDs, representing an affinity loss of >10– to 20-fold. Our yeast immunoassay is easily tailored, expandable and parallelized with newly emerging RBD variants.http://www.sciencedirect.com/science/article/pii/S2589004223007253Health sciencesImmunologyDiagnosticsVirology |
| spellingShingle | Joanan Lopez-Morales Rosario Vanella Tamara Utzinger Valentin Schittny Julia Hirsiger Michael Osthoff Christoph T. Berger Yakir Guri Michael A. Nash Multiplexed on-yeast serological assay for immune escape screening of SARS-CoV-2 variants iScience Health sciences Immunology Diagnostics Virology |
| title | Multiplexed on-yeast serological assay for immune escape screening of SARS-CoV-2 variants |
| title_full | Multiplexed on-yeast serological assay for immune escape screening of SARS-CoV-2 variants |
| title_fullStr | Multiplexed on-yeast serological assay for immune escape screening of SARS-CoV-2 variants |
| title_full_unstemmed | Multiplexed on-yeast serological assay for immune escape screening of SARS-CoV-2 variants |
| title_short | Multiplexed on-yeast serological assay for immune escape screening of SARS-CoV-2 variants |
| title_sort | multiplexed on yeast serological assay for immune escape screening of sars cov 2 variants |
| topic | Health sciences Immunology Diagnostics Virology |
| url | http://www.sciencedirect.com/science/article/pii/S2589004223007253 |
| work_keys_str_mv | AT joananlopezmorales multiplexedonyeastserologicalassayforimmuneescapescreeningofsarscov2variants AT rosariovanella multiplexedonyeastserologicalassayforimmuneescapescreeningofsarscov2variants AT tamarautzinger multiplexedonyeastserologicalassayforimmuneescapescreeningofsarscov2variants AT valentinschittny multiplexedonyeastserologicalassayforimmuneescapescreeningofsarscov2variants AT juliahirsiger multiplexedonyeastserologicalassayforimmuneescapescreeningofsarscov2variants AT michaelosthoff multiplexedonyeastserologicalassayforimmuneescapescreeningofsarscov2variants AT christophtberger multiplexedonyeastserologicalassayforimmuneescapescreeningofsarscov2variants AT yakirguri multiplexedonyeastserologicalassayforimmuneescapescreeningofsarscov2variants AT michaelanash multiplexedonyeastserologicalassayforimmuneescapescreeningofsarscov2variants |